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Abstract
The PD-1 (programmed death 1) molecule is a negative
regulator of T cells. PDCD1 (programmed cell death 1) has
been reported to have a genetic association in systemic lupus
erythematosus and rheumatoid arthritis in Caucasians.
However, there are no reports on the association between this
gene and ankylosing spondylitis (AS). The present study
investigated the association of the PD-1 polymorphisms and the
haplotypes with AS in a Korean population sample. In a case-
control association study, two single-nucleotide polymorphisms,
PD-1.5 C/T and PD-1.9 T/C, were genotyped in 95 AS patients
and 130 healthy controls. The T allele of the PD-1.9
polymorphism was more frequent in the Korean male population
with AS than in the Korean male controls (21.0% versus 6.9%,
odds ratio 1.89, 95% confidence interval 1.483 to 2.408). The
frequency of the CT haplotype (PD-1.5 C/T and PD-1.9 T/C)
was higher in the AS patients (19%) than the controls (5.4%)
(odds ratio 1.83, 95% confidence interval 1.559 to 2.521). The
PD-1 polymorphism was demonstrated in Korean AS patients.
The results suggest a genetic association between the PD-1
polymorphism and susceptibility to AS.
Introduction
Ankylosing spondylitis (AS) is an important chronic inflamma-
tory disease with an incidence range of between 0.5% and
1.0% [1,2]. Many genetic and environmental factors have
been suggested to have some role in the development of AS
[3]. However, the pathogenesis of AS is still unclear. Human
leukocyte antigen (HLA) B27 makes up only a small proportion
of the overall risk for spondyloarthritis. Fewer than 5% of HLA-
B27-positive people in the general population develop these
diseases [4]. In contrast, 20% of the HLA-B27-positive rela-
tives of AS patients are affected. Family studies have sug-
gested that HLA-B27 contributes to about 37% of the overall
genetic risk for spondyloarthritis [5-7], which suggests the
involvement of other genes in the development of AS. Another
new susceptible gene therefore needs to be identified.
Recently, the PDCD1 (programmed cell death 1) gene poly-
morphism was reported to be associated with systemic lupus
erythematosus (SLE) [8,9], lupus nephritis [10,11] and seron-
egative rheumatoid arthritis (RA) [12]. It was also suggested
that lupus nephritis and the seronegative RA susceptibility was
associated with the PD-1.3 (position 7,146) A allele in a north-
ern Sweden population.
The PD-1 molecule is a negative regulator of T cells [13] that
belongs to the immunoglobulin receptor superfamily. It
encodes a 55 kDa type 1 transmembrane inhibitory immunore-
ceptor and is responsible for the negative regulation of T-cell
activation and peripheral tolerance [14]. Nishimura and Honjo
[15] reported that PD-1 expression was observed only in acti-
vated T and B cells as well as in the early lymphoid precursors.
AS = ankylosing spondylitis; HLA = human leukocyte antigen; OR = odds ratio; RA = rheumatoid arthritis; RFLP = restriction-fragment-length poly-
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PD-1 is actively expressed on the cell surface during the acti-
vation of T and B cells. The cytoplasmic immunoreceptor tyro-
sine-based inhibitory motif of PD-1 was activated by an
interaction between PD-1 and its corresponding ligands, PDL-
1 (B7-H1) and PDL-2 (B7-DC) [15,16], which induces the
inhibitory signal to inhibit the proliferation of T and B cells to
maintain peripheral tolerance [14-16].
The human gene encoding PD-1, PDCD1, is localized on
2q37.3, which is a susceptibility locus for SLE [10]. Allele T of
a single-nucleotide polymorphism (SNP) corresponding to
PD-1.5 C/T (dbSNP rs#cluster id rs2227981) was found to
be associated with the development of RA (odds ratio (OR)
1.94, 95% confidence interval (CI) 1.25 to 3.01, p < 0.0025)
but not SLE in Chinese patients living in Taiwan [17].
So far more than 30 SNPs have been identified. Among the 30
SNPs, 7 (namely PD-1.1, PD-1.2, PD-1.3, PD-1.4, PD-1.5,
PD-1.6 and PD-1.9) were examined in SLE [12]. Two SNPs
(PD-1.5 C/T (rs2227981) and PD-1.9 T/C/(rs2227982))
were selected because they occur in an exon, which affects
protein synthesis. The change in PD-1.9 T/C causes a change
in their synthesized amino acid from valine to alanine. Our
study was therefore focused on determining whether PD-1.9
T/C SNP affects the development of AS.
Overall, PDCD1  is a strong candidate for susceptibility to
autoimmune disease. This study therefore investigated
whether or not PDCD1 is associated with AS in the Korean
population.
Materials and methods
Patients and control subjects
Case-control genetic association studies were performed to
test the association between PDCD1 and the development of
AS. The patient group consisted of 95 Korean patients with
AS who were recruited from the Kyunghee University Medical
Center, Seoul, Korea. A diagnosis of AS was established by
using the classification criteria reported by the American Col-
lege of Rheumatology (Modified New York Criteria). At least
two rheumatologists confirmed the diagnosis. The patients
were diagnosed before March 2005 and samples of whole
blood was extracted between March 2003 and February
2005. The other control group was made up of 130 normal
individuals who underwent a health examination in Kyunghee
University Medical Center. They had no previous medical his-
tory and no abnormal laboratory results. All subjects provided
written informed consent. All medical records in both groups
were reviewed and analysed according to age, gender, com-
bined disease, complications and disease duration.
This study was approved by the ethics review committee of the
Medical Research Institute at Kyung Hee University Medical
Center, Seoul, Korea in accordance with the World Medical
Association Declaration of Helsinki: Ethical Principles for Med-
ical Research Involving Human Subjects.
Genotyping of PD-1.5 and 1.9
Samples of peripheral blood were obtained from all partici-
pants after receiving informed consent. The genomic DNA
was extracted from the EDTA-treated whole blood with the
Wizard® Genomic DNA Purification Kit (Promega, San Luis
Obispo, CA, USA). PCR amplification was performed with 50
ng of the genomic DNA in a 25 μl reaction volume containing
10 pmol of sense primer in 0.5 μl, 10 pmol of antisense primer
in 0.5 μl, 0.5 μl of 2.5 mmol/l dNTP (Takara, Shiga, Japan), 1
U of tag DNA polymerase (Takara), and a buffer provided by
the manufacturer. The samples were subjected to 35 amplifi-
cation cycles in an icycler™ Thermal Cycler (Bio-Rad, Her-
cules, CA, USA). The subsequent restriction-fragment-length
polymorphism (RFLP) analysis was performed to determine
the PD-1.5 C/T (dbSNP rs#cluster id. rs2227981) and PD-
1.9 C/T (dbSNP rs#cluster id. rs2227982) SNPs using Alu I
(New England Biolabs Inc., Beverly, MA, USA) and Bpu 10I
(New England Biolabs Inc), respectively (Table 1) [5]. Figure
1 shows the agarose gel electrophoresis results after RFLP.
Statistical analysis
The SPSS statistical package (version 10.0) was used for sta-
tistical analysis. The data are expressed as means ± SD. The
baseline differences between the groups were tested with
Student's t test and a χ2 test. All the SNP analyses, such as
Hardy–Weinberg equilibrium test, linkage disequlibrium and
haplotype inference, were performed with SNP Alyze (version
5.1; DYNACOM). Hardy–Weinberg equilibrium, which indi-
cates the absence of any discrepancies between the geno-
type and allele frequencies, was examined and no
discrepancies were noted. SNP Alyze was used to examine
Table 1
PCR-RFLP methods, PCR primers and restriction enzymes (RE).
Polymorphism SNP Location Method RE PCR primers
PD-1.5 7785C/T Exon 5 PCR-RFLP Alu I 5' -AGACGGAGTATGCCACCATT-3'
5' -CACTGTGGGCATTGAGACAT-3'
PD-1.9 7625C/T Exon 5 PCR-RFLP Bpu 10I 5' -GGACAGCTCAGGGTAAGCAG-3'
5' -AGGGTCTGCAGAACACTGGT-3'
SNP, single-nucleotide polymorphism; PCR, polymerase chain reaction; RFLP, restriction-fragment-length polymorphism.Available online http://arthritis-research.com/content/8/6/R163
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the allele frequency and haplotype. There was no linkage dis-
equilibrium or haplotype inference. The ORs and 95% CIs of
the allele frequencies and haplotypes were calculated in the
control and disease groups. The allele frequencies were com-
pared by using a χ2 test with a 2 × 2 contingency table. A χ2
test was also used to compare the haplotype frequencies. p ≤
0.05 was considered significant.
Results
Basal characteristics of patients with ankylosing 
spondylitis and of normal controls
Table 2 shows the basal characteristics and combined dis-
ease of the subjects. In brief, there were 83 idiopathic AS
patients. The other patients had inflammatory bowel disease,
reactive arthritis or psoriasis. Their age at onset, age at diag-
nosis and duration from initial symptoms to diagnosis were
23.1 ± 7.6 years, 25.9 ± 8.5 years and 32.1 ± 38.2 months,
respectively. The percentages of patients with uveitis and
peripheral joint involvement were 8.4% and 29.4%, respec-
tively.
PD-1.5 SNP in patients with ankylosing spondylitis and 
in normal controls
A total of 225 subjects (95 patients and 130 controls) were
genotyped for PD-1.5 C/T SNPs. Among the 95 AS patients,
42.0%, 49.4% and 8.6% had the C/C, C/T and T/T geno-
types, respectively; among the 130 normal controls these pro-
portions were 40.8%, 39.2% and 20.0%, respectively. Among
the 95 AS patients, the allele frequencies of C and T were
66.7% and 33.3%, respectively, and 60.8% and 39.2%
among the normal controls. There was no significant differ-
ence between the PD-1.5 C/T SNPs and uveitis, peripheral
joint involvement, total hip replacement and gender (Table 3).
PD-1.9 SNP in patients with ankylosing spondylitis and 
normal controls
A total of 225 subjects (95 patients and 130 controls) were
genotyped for the PD-1.9 T/T SNPs. Among the 95 AS
patients, 2.5%, 37.5% and 60.5% had the T/T, C/T and C/C
genotypes, respectively; among the 130 normal controls the
proportions were 2.3%, 9.2% and 88.5%, respectively. There
was a significant difference between the groups in C/T versus
C/C but no significant difference in C/C versus T/T. Among
the 95 AS patients, the allele frequencies of T and C were
21.0% and 79.0%, respectively, and 6.9% and 93.1% among
the controls. There was a statistically significant difference
between the groups, and the 95% CI 1.483 to 2.408, OR was
1.89 according to the χ2 test (Table 3).
Haplotype analysis
Among the 95 AS patients, 19.1%, 47.5%, 1.9% and 31.5%
had the CT (PD-1.5 C/T and PD-1.9 T/C), CC, TT and TC hap-
lotype, respectively; among the 130 normal controls the pro-
portions were 5.4%, 55.4%, 1.5% and 37.7%, respectively.
The frequency of the CT haplotype was higher in the AS
patients than the controls (OR 1.83; 95% CI 1.559 to 2.521;
Table 3).
Discussion
The results show that a functionally important polymorphism in
PDCD1 is associated with a subset of AS. A polymorphism in
this gene has previously been shown to be associated with
SLE [8,9] and RA [12]. These results suggest that this gene
may commonly have some role in the development of autoim-
mune disease. PDCD1 has a key role in the immune response
as follows.
The ligands for PD-1 have been identified as PD-L1 (B7-H1),
which is expressed in all haemopoietic cells as well as in many
Figure 1
Gel electrophoresis patterns of PD-1 Gel electrophoresis patterns of PD-1.5 and PD-1.9. (a) The amplified fragments of PD-1.5 were digested with Alu I: the polymerase chain reaction 
(PCR) product size was 333 base pairs (bp), which was digested to 264 and 69 bp. If the product was digested, the allele was identified as T; if not, 
it was identified as C. (b) The amplified fragments of PD-1.9 were digested with Bpu 10I: the PCR product size was 408 bp, which was digested to 
260 and 145 bp. If the product was digested, the allele was identified as C; if not, it was identified as T.Arthritis Research & Therapy    Vol 8 No 6    Lee et al.
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non-haemopoietic tissues, and PD-L2 (B7-DC), which is
expressed primarily on dendritic cells and macrophages
[14,16,18,19]. This molecule has a role in the negative co-
stimulated pathway involving the CD28 homologue PD-1
receptor [20]. PD-1 is expressed by activated, but not unstim-
ulated, T cells, B cells and myeloid cells, which is in contrast
with the predominantly T-cell-restricted expression of CD28
and CTLA-4 [21-23]. PD-1-/- mice display a variety of autoim-
mune pathologies, including dilated cardiomyopathy (in
BALB/c mice) and a lupus-like syndrome (in B6 mice). This
indicates that PD-1 has a key role in the maintenance of
peripheral tolerance to self-antigens, which is analogous to
that of CTLA-4 [13,24]. The development of AS can therefore
be affected by PD-1 expression or the function of the PD-1
molecule, and is associated with the continuous activation of
immune cells such as CD4+ T cells or dendritic cells. HLA
B27, which is the most important genetic factor for AS, is a
class I antigen and reacts with CD 8+ T cells. However, most
autoimmune diseases are associated with CD4+  T cells.
Recently, misfolding HLA B27 was reported to stimulate
CD4+ T cells or natural killer cells in HLA B27 transgenic rats
[25]. In contrast, it was suggested that HLA B27 itself also
could act as an autoantigen, because it is recognized by the T-
cell receptors on CD4+ T cells [26] or by its presentation by
HLA class II molecules. This suggests the importance of the
CD4+ T-cell activation pathway and termination of its activa-
tion in AS. It is therefore possible that AS is associated with
the function of the PD-1 molecule.
The PD-1 SNP has been examined in several studies but only
in SLE and RA patients. Ferreiros-Vidal and colleagues [9]
studied PD-1.1, PD-1.2, PD-1.3, PD-1.5, PD-1.6 and PD-1.9
SNPs in Spanish patients with SLE. They reported that the
PD-1.9 minor allele was too rare and reported an incidence of
less than 1.1% in 186 patients with SLE and 0% in the control
group of 186 individuals. As a result, there were no more stud-
ies on PD-1.9 SNP. However, the results in the present study
suggest that the PD-1.9 T allele is more frequent in a Korean
population sample than in a Spanish population sample (21%
in patients with AS and 6.9% in controls). The reason for this
difference is that previous studies were confined to females
because of the high female predominance of SLE. It should be
noted that AS develops predominantly in males. Our results
showed no gender difference in the frequency of PD-1.5 or
PD-1.9. The PD-1.5 SNP has been studied extensively in sev-
eral populations. The PD-1.5 C allele was found to be more
frequent in Korean populations than in other populations
(Spanish, Swedish, European and American Mexican). The
data are shown in Table 4. Table 5 shows the data for another
Asian group study, a Chinese population for RA [11]. In that
study the control group was 33% female; in contrast, 41% of
the control group in the present study were female.
The limitation of our study was that the control group was mis-
matched to the disease group in sex and age. With regard to
sex, the polymorphism of this gene is not affected by the sex
difference in our control group. With regard to age, with
increasing age in the control group the possibility of being in
the disease-free group increased because AS develops at a
relatively young age.
The PD-1.9 T allele was found to be a susceptibility factor for
AS; however, 1.5 SNP was not a factor. The PD-1.9 T allele
substitutes valine for alanine 215 during PD-1 protein synthe-
sis. However, other subgroup analyses according to gender,
combined uveitis, the involvement of a peripheral joint and the
existence of HLA B27 showed no significant differences.
Table 2
Basal characteristics and clinical features of patients with AS 
and of normal controls.
Characteristic Patients Controls
Sex, M:F (%) 88:7 (92.6:7.4) 76:54 (58.5:41.5)
Age (mean ± SD) 33.4 ± 9.4 66.3 ± 5.8
Disease subgroup, n
Idiopathic AS 83
IBD 3
Reactive arthritis 2
Psoriatic arthritis 1
JAS 6
Clinical features
Age on initial 
symptom, years 
(mean ± SD)
23.1 ± 7.6
Disease duration, 
months (mean ± 
SD)
25.9 ± 8.5
Delayed 
diagnosis, months 
(mean ± SD)
32.1 ± 38.2
HLA B27+ (n = 
84) (%)
74 (88.1)
Complications, n (%)
Uveitis 8 (8.4)
Peripheral joint 
involvement
28 (29.4)
Total hip 
replacement
13 (13.5)
IgA nephropathy 0 (0)
Heart conduction 
abnormality
0 (0)
Pneumonitis 0 (0)
Cauda equina 
syndrome
3 (3.1)
AS, ankylosing spondylitis; IBD, inflammatory bowel disease; JAS, 
juvenile ankylosing spondylitis; HLA, human leukocyte antigen.Available online http://arthritis-research.com/content/8/6/R163
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Therefore, further study will be needed to determine whether
this amino acid change alters the protein structure and affects
its function.
Conclusion
PDCD1 was known as another genetic risk factor in RA or
SLE patients. However, there was no known study on this
gene with regard to AS. We have examined the association
between this autoimmune-associated gene and AS and con-
cluded that the gene is associated with susceptibility to AS,
although only a small sample was used. We believe that these
results are sufficient to suggest another genetic susceptibility
(PDCD1) for AS.
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Table 5
Differences in PD-1.5 genotype and alleles between Korean 
and Chinese populations.
Characteristic Korean controls (%) Chinese controls (%)
Characteristic Korean controls (%) Chinese controls (%)
CC 53 (40.8) 333 (51.5)
CT 51 (39.2) 259 (40.0)
TT 26 (20.0) 55 (8.5)
Allele frequency
C 158 (60.8) 925 (71.5)
T 102 (39.2) 369 (28.5)
Chinese data from [17].
Table 3
Genotyping and allele frequency and haplotype of PD-1.5 and PD-1.9 SNP in patients and controls.
SNP Alleles Patients (%) Controls (%) OR (95% CI)
PD-1.5 CC 34 (42.0) 53 (40.8)
CT 40 (49.4) 51 (39.2)
TT 7 (8.6) 26 (20.0)
C 108 (66.7) 158 (60.8)
T 54 (33.3) 102 (39.2)
PD-1.9 TTa 2 (2.5) 3 (2.3)
CT 30 (37.5) 12 (9.2)
CCb,c 49 (60.5) 115 (88.5)
Td 34 (21.0) 18 (6.9) 1.89 (1.483–2.408)
C 128 (79.0) 242 (93.1)
PD-1.5/1.9 (haplotype) CTe 31 (19.1) 14 (5.4) 1.83 (1.559–2.521)
CC 77 (47.5) 144 (55.4)
TT 3 (1.9) 4 (1.5)
TC 51 (31.5) 98 (37.7)
SNP, single-nucleotide polymorphism; OR, odds ratio; CI, confidence interval. ap = 0.000, χ2 test, in PD-1.9 SNP ; bp = 0.638, χ2 test, CC versus 
TT; cp = 0.000, χ2 test, CC versus CT ; dp = 0.000, χ2 test, in PD-1.9 SNP; ep = 0.000, χ2 test, in PD-1.5/1.9 haplotype analysis.
Table 4
Differences in PD-1.5C allele frequencies between Korean 
female control population and other female populations.
Population n/N (%)
Korean 68/108 (63.0)
Spanish 540/984 (54.9)
Swedish 220/404 (54.4)
European American 84/160 (52.5)
Mexican 215/360 (59.7)Arthritis Research & Therapy    Vol 8 No 6    Lee et al.
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